InsidersTradesSigma
Follow the SK바이오사이언스 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are listed on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, SK바이오사이언스 has logged 2 reports. Market capitalisation: €2,698.9bn. The latest transaction was reported on 27 March 2026 (Purchase). Among the most active insiders: SK케미칼. All data is openly available.
2
Insider Decl.
n/a
Thresholds
€115,619
2 ops.
Buy Volume
n/a
n/a
Sell Volume
10Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,414 of 28,803 companies
20.0
score / 100
Value24
Quality17
FCF yld-5.8%
Earn yld-2.1%
EV/EBITDA·
ROE-4.3%
Gross mgn12%
Net mgn-8.8%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 March 2026
About SK바이오사이언스
SK Bioscience is a South Korean company focused on the development and manufacturing of vaccines and biologics. It is listed on the XKRX market.